Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Negative long-term effect on cardiac function in babies born from diabetic mothers. Having a disease such as diabetes has many risks and long-term possible cardiovascular effects if not managed well. Furthermore, being a diabetic pregnant patient has even more risks and can lead to complications maternally and congenital complications and …
Read More »Dulaglutide versus Insulin Glargine for Type 2 Diabetes
Does a once-weekly dulaglutide provide similar efficacy compared to basal insulin for patients with type 2 diabetes? In the pharmacological options available for type 2 diabetes, basal insulin such as insulin glargine is an effective method in control fasting blood sugar. However, the use of insulin is associated with hypoglycemia …
Read More »Pharmacist-Led Education on Diabetes Increased Medication Adherence in Patients with T2D
Education on T2D can significantly reduce A1C and systolic blood pressure after six months. Patients with T2D require strict medication adherence, a task many individuals find difficult to achieve. Following the recommended diet and exercise regimen to attain weight loss are also essential for glycemic control. This study looked at …
Read More »The role of long-term exposure to Bisphenol A on insulin resistance in patients with type 2 diabetes
In humans with and without DM, exposure to BPA could interfere with insulin signaling pathways and cause insulin resistance. The burden of diabetes type 2 (T2D) has emerged as one of the leading causes of death worldwide is a significant healthcare concern worldwide. In addition to known risk factors for …
Read More »Patients with diabetes and HF on Metformin and Sulfonylurea show improved clinical outcomes
In patients with type 2 diabetes mellitus, composite mortality/HHF was significantly lower in patients taking metformin versus those taking sulfonylurea.The rising global burden of diabetes and its complications in recent years has called for new Prevention and control programs and alternative treatment approaches for existing treatments based on evidence-based treatment …
Read More »Glucose Management Indicator in Diabetes
According to research presented by Dr. Elena Toschi from Harvard Medical School, a more significant difference between Hba1c and GMI was associated with a higher risk of low blood glucose. A disparity between HbA1c and mean glucose estimated by self-blood glucose observing and continuous glucose monitoring (CGM) has been depicted in …
Read More »Health Disparities among People with Diabetes in America and The Relationship of Race, Economic Status, and Ethnicity in Contributing to Health Inequality
Research results show that race, ethnicity, and socio-economic disparity influence the uptake of GLP-1 RA medication among people with diabetes which suggests that they are critical determinants of health. The issue of diabetes has been a topic for research over a long duration of time. Therefore, research is undertaken to …
Read More »DPP-4 Inhibitors Vs. Sulphonylureas As Add-On to Metformin – Assessing CV Outcomes in Type 2 Diabetes
New retrospective study results compare the two most largely prescribed antidiabetic medication classes in addition to metformin, to determine the impact on the incidence of CV events in patients with T2DM. Dipeptidyl-peptidase-4 inhibitors (DPP-4i) and sulphonylureas (sulfonylureas in the US) (SU) are two of the most prescribed medication to date …
Read More »Type 2 Diabetes: The Impact of Vision and Hearing Impairments on CV Risk Outcomes and Mortality
A comprehensive study reveals the importance of ophthalmologic and otologic care in patients with T2DM due to the association of increased risks for cardiovascular events in those with a decline in vision and hearing abilities. It is known that patients with type 2 diabetes mellitus (T2DM) have an increased risk …
Read More »Pioglitazone, the go-to therapy
Many drugs have CV benefits, reduce HA1c, have metabolic effects, and improve NASH/NAFLD in people with diabetes. Still, pioglitazone, an SGLT2 inhibitor, seems to be one of the cheap drugs and has many functions with more significant benefits than risk. There are a lot of CV trials conducted like the …
Read More »